Israel · Delayed Price · Currency is ILS · Price in ILA Teva Pharmaceutical Industries Earnings Call Transcripts
Fiscal Year 2026
-
The company accelerated its transformation to biopharma in 2025, with innovative products driving 35% growth and a robust late-stage pipeline targeting over $13 billion in peak sales. Key launches and data readouts are set for 2026 and beyond, while cost efficiency and disciplined capital allocation underpin strong EBITDA and free cash flow outlook.
-
The company is accelerating its transformation into a biopharma leader, with strong growth in both generics and innovative products. Key assets like AUSTEDO, UZEDY, and a robust pipeline are expected to drive significant revenue and margin expansion, supported by strategic partnerships and disciplined capital allocation.
-
Duvakitug's phase II study in UC and CD showed strong, durable efficacy and a favorable safety profile, with 58% clinical remission in UC and 55% endoscopic response in CD at 44 weeks. The program is advancing rapidly into phase III, aiming for best-in-class status in a large, competitive IBD market.
-
The conference highlighted a robust immunology R&D strategy, with a focus on validated targets, AI-driven antibody design, and both internal and external innovation. Key programs include an IL-15 antibody for vitiligo and celiac disease, and duvakitug for UC and Crohn's, both aiming for best-in-class efficacy and safety.
-
A multi-year transformation has shifted the business from generics to biopharma, delivering 11 quarters of growth and a robust pipeline with $10B+ peak sales potential. Key launches and data readouts are expected annually, with disciplined financial management and strategic partnerships supporting long-term value creation.
Fiscal Year 2025
-
Delivered strong 2025 results with double-digit growth in innovative products and stable generics. 2026 guidance anticipates continued margin expansion, robust pipeline milestones, and progress toward deleveraging and long-term financial targets.
-
A multi-year transformation to biopharma is driving margin expansion and EBITDA growth, fueled by innovative launches like AUSTEDO, UZEDY, and a robust late-stage pipeline. Strategic capital allocation and disciplined commercial execution underpin sustained financial performance.
-
Medicare Part D discounts for AUSTEDO are now set, with growth expected from underdiagnosed populations. UZEDY and LAI olanzapine show strong commercial momentum, while pipeline assets like Duvakitug and a TSLP IL-13 bispecific advance in clinical development.
-
Austedo achieved the lowest HHS price through strategic planning, with strong growth expected from olanzapine and Duvakitug launches. EBITDA and cash flow are projected to rise despite flat revenue, supported by operational efficiencies and a robust pipeline.
-
Management outlined a robust growth strategy centered on innovative products, disciplined cost control, and a late-stage pipeline with multiple near-term catalysts. Despite a $1B revenue loss in 2026, EBITDA is set to grow, with AUSTEDO, UZEDY, and olanzapine driving future performance.
-
A strategic pivot has driven sustained growth, with innovative products like Austedo and UZEDY showing strong performance and disciplined value management. The pipeline is advancing rapidly, and capital allocation remains focused on long-term value, with portfolio adjustments such as the TAPI divestiture supporting the biopharma vision.
-
Q3 2025 saw 3% revenue growth to $4.5B, led by a 33% rise in innovative products and strong Austedo performance. Guidance for 2025 was tightened, with higher Austedo outlook and reaffirmed 2027 targets, while cost savings and debt reduction remain on track.
-
Atebimetinib plus chemo nearly doubled nine-month overall survival in first-line pancreatic cancer, with robust efficacy and tolerability across endpoints and patient subgroups. A pivotal Phase III trial is planned, supported by strong funding and strategic partnerships.
-
Management outlined a disciplined capital allocation strategy, prioritizing debt reduction, innovation, and operational efficiency. Growth is driven by a robust pipeline, including Austedo, olanzapine LAI, and DARI, with cost savings and market expansion supporting long-term value.
-
The SOLARIS phase III study of subcutaneous Olanzapine LAI demonstrated strong efficacy and safety, with no PDSS cases in nearly 4,000 injections and clinically meaningful symptom improvements. The formulation addresses key adherence and safety challenges, positioning it for rapid adoption and significant impact on relapse and hospitalization rates.
-
A robust strategic shift has driven sustained growth, with innovative products now at the core and a strong pipeline targeting $11–13 billion in peak sales. Generics remain a key cash generator, supporting investment in biopharma assets, while disciplined capital allocation and execution underpin long-term financial targets.
-
Q2 2025 marked the 10th consecutive quarter of growth, with revenue up 1% in local currency, driven by strong performance in AUSTEDO, UZEDY, and AJOVY. Guidance for all three products was raised, and transformation programs are on track, supporting margin expansion and debt reduction.
-
The acceleration phase focuses on commercializing innovative products and expanding the late-stage pipeline, with generics providing stability and cash flow. Margin expansion and strict capital allocation support growth, while the pipeline and partnerships target significant unmet needs in neuro, INI, and rare diseases.
-
The conference highlighted a strategic pivot to growth, with strong performance from key assets and a robust pipeline featuring three phase 3 programs. Ozethro and Austedo are set for significant sales growth, while innovative products like TL1A and DARE show strong clinical promise. Manufacturing and supply chain risks are actively managed.
-
A robust transformation is underway, shifting from generics to biopharma with a strong late-stage pipeline, innovative launches, and disciplined capital allocation. Financial targets for 2027 and 2030 are supported by margin expansion, cost optimization, and a diversified revenue base.
-
Ninth consecutive quarter of growth with revenue up 5% to $3.9B, led by innovative brands and generics. 2025 guidance raised for AUSTEDO and EPS, with $700M in transformation savings targeted by 2027 and a clear path to 30% operating margin.
-
A clear pivot to growth has driven eight quarters of expansion, with innovation and operational efficiency at the core. Key products like Austedo, Uzedy, and Ajovy are set for strong growth, while new launches and cost programs support margin targets and a robust 2027 outlook.
-
Management outlined a four-pillar growth strategy, highlighted strong revenue momentum, and detailed confidence in EBITDA growth through 2027, supported by innovative products, efficiency programs, and the TAPI divestment. Product launches and a resilient supply chain underpin long-term value.
-
Phase IIb data show Duvakitug achieved significant clinical and endoscopic remission rates in both ulcerative colitis and Crohn's disease, with a favorable safety profile and low immunogenicity. Efficacy was robust across patient subgroups, supporting advancement to phase III.
-
A strategic pivot has transformed the company into a global biopharma leader, delivering seven quarters of growth and accelerating its innovative pipeline. Key products Austedo, Uzedy, and Ajovy are driving revenue, while a robust pipeline and biosimilars portfolio support future targets through 2027.
Fiscal Year 2024
-
2024 saw 9% revenue and EBITDA growth, driven by strong performance in innovative and generics segments, with AUSTEDO, AJOVY, and UZEDY leading gains. 2025 guidance anticipates continued growth, stable margins, and ongoing investment in pipeline and debt reduction.
-
Duvakitug achieved robust, statistically significant phase IIb results in both ulcerative colitis and Crohn's disease, with strong efficacy, favorable safety, and low immunogenicity. Phase III trials are planned for 2025, and the program is expected to drive further innovation and growth.
-
A four-pillar growth strategy is driving innovation, pipeline expansion, and operational focus, with key products like Austedo and long-acting olanzapine positioned for significant growth. Major clinical milestones are expected for TL1A and ICS/SABA, while new biomarker and early-stage studies advance.
-
A detailed growth strategy has driven seven consecutive quarters of expansion, with innovative products and generics both outperforming expectations. Key pipeline assets, including TL1A and olanzapine, are advancing, and 2027 financial targets remain on track.
-
Q3 2024 saw 15% revenue growth, strong gains in innovative and generics portfolios, and raised full-year guidance. Key products Austedo, Ajovy, and Uzedy drove performance, while biosimilars and pipeline assets advanced. Net debt and credit ratings improved.
-
GSK has executed a strategic pivot to a focused biopharma model, delivering strong financial results and pipeline progress, especially in specialty care and vaccines. Growth is expected from international expansion, new product launches, and margin improvement, while Zantac litigation and evolving market dynamics remain key watchpoints.
-
The company is executing a multi-pillar growth strategy, with strong momentum in innovative products, generics, and biosimilars. Key products like Austedo, Ajovy, and Uzedy are driving growth, while pipeline assets and dynamic capital allocation support future expansion.
-
Q2 2024 saw 11% local currency revenue growth to $4.2B, driven by innovative and generics segments, with AUSTEDO, UZEDY, and biosimilars performing strongly. Full-year guidance for revenue, EBITDA, and EPS was raised, and the pipeline advanced with key late-stage assets.
-
The company is executing a focused growth strategy by reallocating capital to innovation, streamlining its generics pipeline, and driving performance through disciplined measurement. Key products and pipeline assets are expected to fuel growth through 2027, with a strong emphasis on CNS, immunology, and biosimilars, while maintaining a cautious outlook on U.S. generics pricing.